Trial Profile

Study of Allisartan isoproxil in the treatment of mild to moderate Essential Hypertension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allisartan (Primary) ; Amlodipine; Indapamide
Indications Essential hypertension
Focus Therapeutic Use

Most Recent Events

12 Jun 2023 Results assessing clinical efficacy for essential hypertension, published in the American Journal of Hypertension.
04 May 2023 New trial record
06 Mar 2023 Results presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com